NEW YORK and WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to ...
NEW YORK and WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody ...
NEW YORK and WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody ...
NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody ...
Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing Phase ...
Fintel reports that on December 22, 2025, Wedbush reiterated coverage of Dianthus Therapeutics (NasdaqCM:DNTH) with a Outperform recommendation. Analyst Price Forecast Suggests 57.21% Upside As of ...
Dianthus Therapeutics to present at J.P. Morgan Healthcare Conference on January 15, 2025, discussing antibody therapies for autoimmune diseases. Dianthus Therapeutics, Inc., a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback